✦ LIBER ✦

A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer

✍ Scribed by Juan Bayo; María Lomas; Javier Salvador; Alberto Moreno; Manuel Ruiz; Alberto Rodríguez; José Fuentes; Ana Fernández-Freire; Reyes Bernabé; Andrea Fernández

Book ID: 107596449
Publisher: Springer Milan
Year: 2008
Tongue: Spanish
Weight: 332 KB
Volume: 10
Category: Article
ISSN: 1699-048X
DOI: 10.1007/s12094-008-0295-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II multicentre study of docetaxel

Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer

✍ Lortholary, A; Delozier, T; Monnier, A; Bourgeois, H; Bougnoux, P; Tubiana-Mathi 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 101 KB

A phase II randomized study comparing na

A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer

✍ M. Ghosn; P. Aftimos; F. S. Farhat; J. G. Kattan; C. Hanna; N. Haddad; F. Nasr; 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 447 KB

Phase II study of capecitabine and trast

Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes

✍ Takanori Ishida; Takayoshi Kiba; Motohiro Takeda; Kotone Matsuyama; Satoshi Tera 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 367 KB

Phase 2 study of neoadjuvant treatment w

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer

✍ A. J. Montero; C. M. Diaz-Montero; Y. E. Deutsch; J. Hurley; L. G. Koniaris; T. 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 398 KB

A multicenter randomized phase II study

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

✍ Jean-Yves Pierga; Suzette Delaloge; Marc Espié; Etienne Brain; Brigitte Sigal-Za 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 236 KB